Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial-Reference-Cited by-同舟云学术

Progression-Free Survival and Local Control After SABR for up to 5 Oligometastases: An Analysis From the Population-Based Phase 2 SABR-5 Trial

Published:2022-11 Issue:4 Volume:114 Page:617-626
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Baker Sarah,Jiang Will,Mou Benjamin,Lund Chad R.,Liu Mitchell,Bergman Alanah M.,Schellenberg Devin,Alexander Abraham S.,Carolan Hannah,Atrchian Siavash,Chng Nick,Matthews Quinn,Arbour Gregory,Benny Alexander,Tyldesley Scott,Olson Robert A.

Publisher

Elsevier BV

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,Radiation

Reference25 articles.

1. Oligometastases;Hellman;J Clin Oncol,1995

2. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial;Ost;J Clin Oncol,2018

3. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial;Phillips;JAMA Oncol,2020

4. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: A phase 2 randomized clinical trial;Iyengar;JAMA Oncol,2018

5. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial;Palma;Lancet,2019

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclin-dependent kinase 4/6 inhibitors combined with stereotactic ablative radiotherapy in oligometastatic HR-positive/HER2-negative breast cancer patients;British Journal of Radiology;2024-08-09

2. Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer;Radiotherapy and Oncology;2024-07

3. Advancing the Paradigm: Oligometastatic Disease and the Impact of Stereotactic Ablative Body Radiotherapy;Clinical Oncology;2024-07

4. Hybrid approaches to pulmonary metastasectomy: a narrative review;Video-Assisted Thoracic Surgery;2024-06

5. Upfront Versus Delayed Systemic Therapy in Patients With Oligometastatic Cancer Treated With SABR in the Phase 2 SABR-5 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-04